Key Finding :
It is safe to interrupt endocrine therapy for hormone receptor-positive breast cancer in order to attempt pregnancy. Less than 9% of women in the single-group trial had a breast cancer event over 3 years, a rate similar to external controls.
The international trial, which had participants from ...
